274-80-6

Usage

Uses

1. Used in Chemical Synthesis:
1,7,8-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene is used as a reactive intermediate for the synthesis of various complex organic molecules. Its triaza-donor system and tetraene moiety facilitate unique chemical reactions that can lead to the formation of novel compounds with potential applications in different industries.
2. Used in Pharmaceutical Research:
1,7,8-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene is used as a scaffold in the development of new pharmaceutical compounds. Its unique structure and reactivity allow for the design of molecules with specific biological activities, such as potential drug candidates for various therapeutic applications.
3. Used in Material Science:
1,7,8-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene is used as a building block in the creation of new materials with unique properties. Its incorporation into polymers or other materials can result in enhanced properties such as improved stability, reactivity, or selectivity in certain applications.
4. Used in Analytical Chemistry:
1,7,8-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene is used as a reagent or a reference compound in analytical chemistry. Its distinct chemical properties can be exploited for the development of new analytical methods or for the calibration of analytical instruments.
5. Used in Environmental Applications:
1,7,8-triazabicyclo[4.3.0]nona-2,4,6,8-tetraene is used as a component in the development of environmental remediation technologies. Its reactivity and ability to form complexes with other molecules can be utilized for the removal or degradation of pollutants in the environment.

InChI:InChI=1/C6H5N3/c1-2-4-9-5-7-8-6(9)3-1/h1-5H

Upstream product

• 4930-98-7 pyrid-2-ylhydrazine 
• 64-18-6 formic acid 
• 75-52-5 nitromethane 
• 109-09-1 2-chloropyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 50-00-0 formaldehyd 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 4928-87-4 1,2,4-triazole-3-carboxylic acid 
• 4922-68-3 3-bromo[1,2,4]triazolo[4,3-a]pyridine 
• 59696-86-5 3-benzyl-[1,2,4]triazolo[4,3-a]pyridine 
• 20955-15-1 2-phenyl-[1,2,4]triazolo[4,3-a]pyridin-2-ium tetrafluoroborate 

Relevant academic research and scientific papers

Nitroalkanes as electrophiles: Synthesis of triazole-fused heterocycles with neuroblastoma differentiation activity

We discovered a reaction of nitroalkanes with 2-hydrazinylquinolines, 2-hydrazinylpyridines and bis-2,4-dihydrazinylpyrimidines in polyphosphoric acid (PPA) affording 1,2,4-triazolo[4,3-a]quinolines, 1,2,4-triazolo[4,3-a]pyridines and bis[1,2,4]triazolo[4,3-a:4′,3′-c]pyrimidines, respectively. The reaction expands the scope of heterocyclic annulations involving phosphorylated nitronates, believed to be the electrophilic intermediates formed from nitroalkanes in PPA. Several of the synthesized triazoles showed promising anticancer activity by inducing differentiation in neuroblastoma cancer cells. Due to the urgent need for novel differentiation agents for neuroblastoma therapy, this finding warrants further evaluation of this class of compounds against neuroblastoma.

ASK1 inhibitor and applications thereof

The invention relates to the technical field of medicines, specifically to a compound represented by a formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof, a pharmaceuticalcomposition and a preparation containing the compound, the pharmaceutically acceptable salt, the ester or the isomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt,the ester or the isomer thereof, and applications of the compound, the pharmaceutically acceptable salt, the ester or the isomer thereof in preparation of drugs for treating and/or preventing ASK1-mediated diseases and related diseases.

Metal free [4+1] and [5+1] annulation reactions to prepare heterocycles using DMF and its derivatives as one-carbon source

1,2,4-Triazolo[3,4-a]pyridines and related heterocycles and substituted triazines were commonly discovered scaffolds in a variety of pharmaceutical and agrochemical agents. Herein, we report a highly efficient and practical method using DMF and its derivative for the [4+1] and [5+1] annulation reactions to prepare these heterocycles. This metal free reaction takes advantages of shelf stable DMF as solvent and carbon donor, imidazole chloride as a catalyst, the mild reaction condition tolerates a broad substrate range and substitutes. The prepared 3-unsubstituted 1,2,4-triazolo[3,4-a]pyridine and derivatives allow further introduction of a variety of functional group1 at 3-position.

Copper(i)-catalyzed benzylation of triazolopyridine through direct C-H functionalization

A general and efficient copper-catalyzed benzylation reaction of triazolopyridine with N-tosylhydrazones was developed. This reaction forms a C(sp2)-C(sp3) bond through cross-coupling, and represents an exceedingly practical method t

Synthesis of 1,2,4-Triazolo[4,3-a]pyridines and Related Heterocycles by Sequential Condensation and Iodine-Mediated Oxidative Cyclization

A facile and efficient approach to access 1,2,4-triazolo[4,3-a]pyridines and related heterocycles has been accomplished through condensation of readily available aryl hydrazines with corresponding aldehydes followed by iodine-mediated oxidative cyclizatio

PROTEIN KINASE INHIBITORS (VARIANTS), USE THEREOF IN TREATING ONCOLOGICAL DISEASES AND A PHARMACEUTICAL COMPOSITION BASED THEREON

The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof.

TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS

Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.